Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05025488 · ClinicalTrials.gov registry record · Phase 1
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
A Phase 1 study of Myelofibrosis and Essential Thrombocythemia, sponsored by Marina Kremyanskaya.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05025488: Recruiting Phase 1 study of Myelofibrosis and Essential Thrombocythemia, sponsored by Marina Kremyanskaya.
NCT05025488 is a Phase 1 study of Myelofibrosis and Essential Thrombocythemia that is actively recruiting participants, run by Marina Kremyanskaya. The registered enrollment target is 10 participants, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05025488, a Phase 1 study of Myelofibrosis and Essential Thrombocythemia, is actively recruiting participants, sponsored by Marina Kremyanskaya.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questionnaires, bone marrow biopsies, research lab collection, and standard of care lab draw. This research will be taking place only at The Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.
Primary Outcome
The Dose Limiting Toxicity (DLT) rate, defined as the proportion of patients with at least 1 grade 3 or higher AE considered to be at least possibly related to the treatment with Poly ICLC and CALR vaccines.
Conditions Studied
Interventions
- DRUG Poly ICLC
- DRUG Peptide-based vaccine
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT05025488 shows while recruiting
NCT05025488 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Poly ICLC is the first listed.
NCT05025488 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05025488 about?
NCT05025488 is a clinical study titled "Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm". The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questio...
What is the current status of trial NCT05025488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2023-04-04. Estimated completion is 2027-03.
What conditions does trial NCT05025488 study?
This clinical trial studies the following conditions: Myelofibrosis, Essential Thrombocythemia, MPN.
What interventions are being tested in trial NCT05025488?
The interventions under investigation include: Poly ICLC (DRUG), Peptide-based vaccine (DRUG).
Who is sponsoring clinical trial NCT05025488?
This trial is sponsored by Marina Kremyanskaya, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05025488 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05025488's enrollment target sits among peer trials
10 60th of 61 higher than 1 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
-
A Safety and Tolerability Study of Jaktinib
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI